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Summary Comparisons across Europe suggest that survival from breast cancer is less good in the United Kingdom than in many countries.
The care given in some UK breast cancer units is exemplary. However, it is difficult to escape the conclusion that a substantial number of
women who present with breast cancer receive suboptimal care. Cancer registry-based studies have clearly demonstrated variations
between surgeons and between hospitals in the management of early breast cancer. Although variations in surgical practice per se may have
little impact on survival, there is evidence that differences in the use of systemic adjuvant therapy influence outcome. Five-year survival
seems to be greater in women treated by surgeons seeing more than 30-50 new cases of breast cancer each year. This may be because
such patients are more likely to be treated by a multidisciplinary team and to receive adjuvant therapy. Proposals that would increase the
overall quality of breast cancer care and remove current inequalities must be carefully considered and should then be implemented.
Keywords: breast cancer; variations in practice; treatment; survival
In theUnited Kingdomeach year, around 30 000 new cases ofbreast
cancer are diagnosed (OPCS, 1994; Scottish Health Service, 1996),
and around 15 000 women die from the disease (Office for National
Statistics, 1996; Scottish Health Service, 1996). Breast cancer, by
any standards, is amajorpublic health problem.
From the prevalence figures for one health region it can be esti-
mated that, at any one time, around 250 000 women in the UK
have been diagnosed as having breast cancer (Thames Cancer
Registry, 1995). Most of them are well, without clinical evidence
ofdisease. Around 30 000 women at any one time have metastatic
disease and, on average, 2 years elapse between recurrence and
death (Richards et al, 1993). Women with breast cancer form a
large constituency, and their natural concerns have been the focus
ofconsiderable media interest.
Age-specific breast cancer mortality is falling for all groups,
probably as the result ofadvances in treatment (Quinn et al, 1995).
An increasing body of evidence suggests that outcome, measured
as survival at 5 years, is significantly affected by a variety oftreat-
ment factors. Recent concerns have focused on the question of
how uniformly high-quality breast cancer care can best be deliv-
ered to all women. This debate has involved all specialties in the
discussion of organizational aspects of care, discussions which
have led them at times into the political arena.
The UK government's current target is to achieve a 25% reduc-
tion in breast cancer mortality in the screened population of
women aged 50-64 years (Department of Health, 1995a). The
Health ofthe Nation target is to save approximately 1250 lives per
annum. This represents about 8% of all deaths from breast cancer
in the UK. Achieving a greater reduction in overall mortality will
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DIFFERENCES IN OUTCOME ACROSS
COUNTRIES
Cross-national comparison ofthe incidence and mortality ofbreast
cancer is fraught with difficulty. In particular, countries that have
more efficient systems forrecording deaths frombreast cancerwill
appear to have higher mortality rates. Nevertheless, there is cause
for concern in the finding that, although the incidence of the
disease in the UKis similar to thatin otherEuropean countries and
North America, mortality is higher (Coleman et al, 1993).
According to data from the Eurocare Study (Berrino et al, 1995),
derived from 30 cancer registries in 12 countries, the average
European 5-year relative survival rate is 66.5%. However, in
England and Scotland the figure is onlyjust over 60%.
There is no evidence that breast cancer in UK women differs in
histology or grade from that in similar countries. Nor is there
evidence that women in the UK who have symptomatic breast
disease delay any longer than others in seeking diagnosis. In the
UK, 50-60% ofbreast cancerpatients see their GP within 4 weeks
of developing a breast symptom and more than two-thirds seek
medical assistance within 3 months (Cameron and Hinton, 1968;
Macarthur and Smith, 1981; Nichols et al, 1981). These findings
compare favourably with those reported from other countries
(Fieldman, 1983; GIVIO, 1986; Rossi et al, 1990).
VARIATIONS IN MANAGEMENT AND SURVIVAL
WITHIN THE UK
Wide variations in the management of breast cancer have been
reported in the UK. Such differences have been observed between
clinicians (Chouillet et al, 1994), between hospitals (Richards et
al, 1996) and between health districts (Sainsbury et al, 1995a).
Variations in survival rates have been reported to depend on
surgical specialization (Gillis and Hole, 1996) and surgical case-
load (Sainsbury et al, 1995b). Socioeconomic deprivation is also
significantly related to poor survival rates (Schrijvers et al, 1995;
Gillis and Hole, 1996).
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Chouillet et al (1994) assessed 334 cases ofbreast cancer diag-
nosed in south-east England in early 1994. Only 46% ofcases had
axillary surgery, and stage was recorded in only 24%. If good
evidence is to be available on case mix, such data must be
recorded as a matter of routine. The information should then be
entered into local databases that can feed into cancer registries.
The data could then be used locally for audit purposes and nation-
ally to monitor variations in practice and outcome.
Sainsbury et al (1995b) investigated outcome in almost 13 000
women treated in Yorkshire between 1979 and 1988 and found
considerable variation in survival between patients treated by
different surgeons. Those who were treated by surgeons with
higher rates of use of chemotherapy and hormone therapy had
better survival. Ifthe practice of surgeons with the better outcome
had been used by all clinicians, overall 5-year survival would have
been increased by 4-5%. Interestingly, such an improvement
would bring the UK close to the European average. The study also
found an apparent effect of caseload: results were poorer among
surgeons treating fewerthan 30 new cases ofbreast cancerper year
than among those who treated more cases. The cut-offpoint of30,
dictated by the limited data available, may not have identified the
optimal caseload, which may be higher than that suggested.
Sainsbury et al also suggest that caseload may be a surrogate
marker for organizational factors such as the availability of multi-
disciplinary teams and on-site cytology and mammography.
The relevance of surgical specialization has recently been
reinforced by a study from the west of Scotland that investigated
the outcome in almost 4000 patients with breast cancer operated
on between 1980 and 1988 (Gillis and Hole, 1996). Adjusted for
prognostic factors, the 5- and 10-year survival rates were 9% and
8% higher among women treated by breast cancer specialists than
among patients treated by non-specialist surgeons. 'Specialists' in
this context were surgeons who were setting up dedicated breast
clinics, who worked with pathologists and oncologists, who
facilitated clinical trials and who maintained a separate record
of breast cancer cases. The survival advantage of specialist care
was evident across all tumour types, nodal status, age and socio-
economic groups.
Along with other regions, substantial and statistically signifi-
cant differences in 5-year mortality are evident between district
health authorities within the West Midlands. These differences in
outcome may be due in part to differences in case mix and in
socioeconomic factors. However, they are probably due, at least in
part, to the fact that access to the best-quality care is not evenly
distributed (D Kerr, personal communication).
A recent study in the Southeast Thames Region (Richards et al,
1996) assessed variations in the management of newly diagnosed
breast cancer specifically in women under50 years ofage. Overthe
period 1984-1988, 1757 such women were identified. They were
cared forby 42 different NHS hospitals in the region, in addition to
seven teaching hospitals in adjacent areas of London. The total
population of the region is 3.5 million, suggesting that each
hospital on average looked after a population of 100 000. Over the
5 years considered, the ten teaching hospitals involved cared for
30% of the breast cancer patients identified. Five non-teaching
hospitals cared for more than 50 new breast cancer patients aged
less than 50 years over the 5-year period, 15 hospitals cared
for between ten and 50 patients and 19 cared for fewer than
ten. This last group of hospitals, which saw on average around
two new patients per year, might represent the first target for the
kind of rationalization suggested by the Department of Health's
document A Policy Framework for Commissioning Cancer
Services (Department of Health, 1995b), commonly known as the
Calman/Hine report.
Over the 1984-88 period studied by Richards et al, the teaching
andnon-teaching hospitals attendedbypatients from the Southeast
Thames Region differed markedly in their management of breast
cancer. This is illustrated by the rates of axillary surgery. In 1984,
67% of cases seen in the teaching hospitals had axillary surgery.
This rate remained relatively constant over the ensuing 4 years.
However, the rate ofaxillary surgery in the non-teaching hospitals,
already significantly lower than in the teaching centres, actually
fell during the period ofstudy -from42% ofcases in 1984 to 27%
of cases in 1988. This decline occurred in spite of the fact that in
1986 the King's Fund Consensus Statement (King's Fund, 1986)
clearly recommended thataxillary lymph nodes should be sampled
at the time ofbreast surgery.
Compared with procedures involved in the diagnosis, staging
and early treatment ofbreast cancer, there is relatively little infor-
mation available about the management of metastatic disease and
possible geographical variations in practice. The majority of
cancer registries keep data only for the first 6 months following
diagnosis. However, information collectedby Gregory et al (1993)
relating to practice at Guy's Hospital over a 16-year period
suggests that second-line chemotherapy was used in surprisingly
few cases. Ofthe 1346 patients who died from breast cancer in the
period 1975-91, only 52% had received chemotherapy at any
stage during the course of their disease. Of this number, only a
third had received more than one regimen. As new drugs become
available, this situation may change and needs to be monitored.
A detailed review ofthe researchevidence related to the issue of
case volumes and outcome for patients with breast cancer was
undertaken in the development of GuidanceforPurchasers (NHS
Executive, 1996). The conclusion drawn was that there is fairly
strong evidence that centres/providers with higher case volume
achieve better clinical long-term outcomes (5-year survival).
However, because of the variable way in which case volume has
been analysed in the literature, it is notpossible precisely to define
a specific volume threshold below which outcomes would be less
than optimal. The manual that accompanies the research evidence
recommends that a specialist breast unit should see at least 100
new cases ofbreast cancer per annum. It should be noted that this
guidance applies to a unit rather than an individual clinician and is
based in part on consideration of the costs of maintaining a full
multidisciplinary team.
THE WAY FORWARD
The Calman/Hine report advocated a two-tier approach to hospital
care. It recommended the establishment of Designated Cancer
Units in many District General Hospitals to manage the more
common cancers, such as that of the breast. Care should be
provided in these units by clinical teams with sufficient expertise
and facilities. Care for the less common cancers, along with more
specialized diagnostic and therapeutic services, should be
provided by Designated Cancer Centres.
In contrast to the fragmentation of services and competition
between Trusts encouraged by recent changes in the NHS, the
Calman/Hine Report urges close links between units and centres,
with arrangements made for common treatment policies, audit
and participation in trials. Given these close connections, the
CalmannHine proposals have been characterized as the 'hub and
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Figure 1
spoke model' for the delivery ofcancer services (Figure 1).
The Calman/Hine Report suggests that different district general
hospitals specialize in different cancers. Surgeons also should
specialize by anatomical site, and only hospitals with enough work
to maintain such subspecialization should become designated
units. Along with this surgical site specialization, the report
emphasizes the importance of multidisciplinary working (notably
between surgical and medical oncology), the need for the
participation of specialized cytologists, oncology nurses and
pharmacists, and the development and implementation of clinical
guidelines.
This broad approach has been supported by several reports from
specialist professional bodies, such as the British Breast Group
(Richards et al, 1994) and the British Association of Surgical
Oncology (Anonymous, 1995), and has been endorsed by the
House ofCommons Select Committee on Health. The importance
of specialist teams that manage an adequate volume of work has
recently been stressed in guidance to purchasers from the
Department ofHealth (NHS Executive, 1996).
However, a number of problems in this approach must be
considered. First, it is vital that sufficient time is allowed fordevel-
opment of the infrastructure that will support the work of the new
cancer units and centres. Unless this is done, the decision by
purchasers to commission breast cancer services only from
specialist teams will result in overload and a reduced quality of
service. Among the support services, mention can be made ofdata
managers: if audit and clinical trial entry are to be pillars of the
new structure, appropriate information technology staffand equip-
ment must be available.
Secondly, the increased demand forappropriately qualified clin-
ical staffcannot immediately be met. There is already a shortage of
suitably trained specialized breast cancer surgeons. Indeed there
may be long term problems in recruiting sufficient surgeons to a
field in which the role of non-surgical oncologists is likely to
become increasingly important. Clearly, there are at present far too
few medical and/or clinical oncologists for their specialism to be
adequately represented in all cancer units. In the UK at present
there are only 70 consultant medical oncologists and about 300
clinical oncologists. This compares with 10 000 board-certified
medical oncologists in the United States.
Thirdly, establishing a consensus on the need forchange will not
be straightforward. The future of district general hospitals that do
not become designated cancer units may be in question. Along
with an accident and emergency department, the provision of
cancer services is perceived as crucial to the viability of many
hospitals. Hospitals attract considerable local loyalty, and threats
to their survival are potentpolitical issues. The prospectofpatients
having to travel further for more specialized cancer treatment is
one that may cause understandable anxiety. Such issues need to be
explored with sensitivity.
Fourthly, increased specialization may mean that there is insuf-
ficient expertise available in district general hospitals to cover
general surgery, including emergencies. Finally, although the idea
of designated units is at the centre of the Calman/Hine proposals,
the process by which units become nationally accredited is not
described.
THE WEST MIDLANDS MODEL
The West Midlands Regional Health Authority, which serves a
population slightly in excess of 5 000 000 and has an annual
standardized breast cancer incidence of about 105 100 000, has
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recently adopted a plan for cancer care that broadly follows the
proposals outlined in the Calman/Hine Report. This region is one
of the furthest advanced in the implementation and testing of the
Calman/Hine recommendations. The aim ofthe new structure is to
achieve a service that is flexible but provides a uniformly high
standard ofcare forthe whole ofthe region's population. Its devel-
opment shows how certain of the concerns about breast cancer
care expressed above can be addressed.
The service to be implemented in the West Midlands follows the
'hub and spoke' model already mentioned. The region will be
served by 16 cancer units, each feeding into one of four cancer
centres. The latter will provide highly specialized surgical and other
services, but each of the units needs to be capable of providing an
integrated breast cancer service. There has been a significant move
towards site specialization by the cancer unit district general
hospital surgeons, with nomination of a head and deputy surgeon
and acceptance within individual trusts that they will be responsible
for coordinating breast care services. Visiting clinical oncologists
will attend the cancer units, coming from the nearest centre
and delivering chemotherapy, when practicable in outpatient
chemotherapy centres established in the units, with central referral
for radiotherapy planning and treatment. The breast cancer
screening centres fit into the regional model in that the largestbreast
cancer practices house the screening centres and it is not envisaged
that these require to be relocated. Approaches have been made to
GPs to help develop shared care protocols for early referral and
follow-up, but these are embryonic and will form part of a future
programme ofwork on patient-centred clinical pathways.
At the hub of the structure is the centre based at the University
of Birmingham CRC Institute for Caticer Studies. This academic
unit will serve the region as a whole and, in addition to its role as
one of the four cancer centres, will provide input from basic
research, act as the focus forthe introduction ofnew therapies, and
design, implement and monitor the full range of clinical trials. It
will also be a centre for the education ofhealth care professionals,
patients and the public.
The new structure embodies the principle of specialization by
site. Surgeons will be asked to reorganize their workload so that
they can meet minimum caseload criteria for individual diseases.
The establishment ofthis critical mass should also provide for the
effective training ofjuniors. Multidisciplinary working is empha-
sized. Surgical and non-surgical specialists are required to call
case conferences; they should havejoint orparallel clinics in adja-
cent sites; consistent referral patterns should be adopted; and suffi-
cient non-surgical oncologists should be in place to provide an
adequate number ofsessions.
The new framework is to be supported by regionally agreed
clinical guidelines developed by disease-specific working parties
comprising senior surgeons, radiotherapists and physicians from
hospitals throughout the region. The guidelines will be updated to
take account of new information and will reflect national guide-
lines produced by the clinical outcomes group (COG). These
guidelines will be accessible to purchasers, their implementation
will be audited and uptake is expected across the entire cancer
network. There will also be guidelines specifying the degree of
support clinicians working within the new system can expect from
radiology, pathology, pharmacy and nursing services. Crucially,
the regional health authority has also commissioned an informa-
tion technology network that will be based in the regional cancer
registry but serve all participating centres and units. This is
regarded as essential as a means of binding together central and
satellite units and also for the purpose of determining whether
the new structure is leading to improvements in mortality and
quality of life. Though regarded as likely, this hypothesis requires
to be tested.
The West Midlands model demonstrates several other features
relevant to those seeking to raise standards and remove inequali-
ties in cancer care. Firstly, its development involved widespread
consultation. The initial blueprint for services was developed by a
Cancer Services Working Group composed of the Clinical
Directors of the four probable Cancer Centres plus leading
specialist physicians and surgical oncologists from throughout the
region. However, the consultation process was extensive: meet-
ings were held with purchasing chief executives, health care
professionals and directors ofpublic health in each ofthe region's
26 district health authorities, and with Trust managers. This was
regarded as essential to create a sense of 'joint ownership'.
Importantly, this process ofextensive consultation did not substan-
tially delay development of the blueprint for services. The final
version of the cancer plan was published in July 1995, only 6
months after the appearance ofthe Working Group's initial recom-
mendations.
Secondly, though the Calman/Hine Report provided the frame-
work and philosophy behind the reorganization, its proposals were
not implemented rigidly. Thus, the West Midlands model also
includes a category ofassociate cancer centre. This was necessary
to allow certain specialized cancer services to continue to be
provided by hospitals that did not meet the strict criteria needed
for designation as a cancer centre. Such associate centres include
the Birmingham Heartland Hospital NHS Trust, which will
provide specialized thoracic surgery, and the provision of paedi-
atric oncology services at the Birmingham Children's Hospital
NHS Trust. Rather than relocating all relevant specialists, this
pragmatic approach - coupled with means ofensuring that multi-
disiplinary working is adopted - was regarded as the best means of
using existing skills.
Thirdly, provision is being made to ensure implementation of
the cancer plan. This will be overseen by a cancer task force
chaired by the Regional Medical Director and including represen-
tatives of clinicians, nurses, patients, purchasers and administra-
tors. Each hospital seeking the status ofa unit or centre is required
to submit a business plan to the task force outlining how it will
fulfil the necessary requirements. These hospitals will then be
visited and appraised, and subsequent performance will continue
to be monitored by visits and by analysis of data provided to the
regional cancer IT network.
Finally, consideration is being given to how the process of
contracting can best be managed. In this initial phase, a range of
options is likely to be explored that will include top-down centre-
to-unit controls, or a service level agreement between units and
centres.
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